ECSP23058246A - Fracciones que prolongan la semivida y métodos de uso de estas - Google Patents

Fracciones que prolongan la semivida y métodos de uso de estas

Info

Publication number
ECSP23058246A
ECSP23058246A ECSENADI202358246A ECDI202358246A ECSP23058246A EC SP23058246 A ECSP23058246 A EC SP23058246A EC SENADI202358246 A ECSENADI202358246 A EC SENADI202358246A EC DI202358246 A ECDI202358246 A EC DI202358246A EC SP23058246 A ECSP23058246 A EC SP23058246A
Authority
EC
Ecuador
Prior art keywords
life
prolong
fractions
methods
prolonging
Prior art date
Application number
ECSENADI202358246A
Other languages
English (en)
Inventor
Stacey Lynn Lee
Andrea Ferrante
Petra Verdino
Josef George Heuer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP23058246A publication Critical patent/ECSP23058246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La descripción se relaciona generalmente con la biología y la medicina, y más particularmente se relaciona con compuestos que actúan como fracciones que prolongan la semivida (t½) para usar con productos terapéuticos, especialmente para mejorar la t½ de productos terapéuticos de base biológica (es decir, biofármacos o productos biológicos). La descripción se refiere además a fusiones y conjugados que incluyen uno o más de los compuestos que actúan como fracciones que prolongan la t½, así como composiciones farmacéuticas que incluyen los mismos y su uso en el tratamiento de diversas afecciones, enfermedades o trastornos.
ECSENADI202358246A 2021-02-02 2023-08-01 Fracciones que prolongan la semivida y métodos de uso de estas ECSP23058246A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02

Publications (1)

Publication Number Publication Date
ECSP23058246A true ECSP23058246A (es) 2023-09-29

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202358246A ECSP23058246A (es) 2021-02-02 2023-08-01 Fracciones que prolongan la semivida y métodos de uso de estas

Country Status (15)

Country Link
EP (1) EP4288452A1 (es)
JP (1) JP2024506145A (es)
KR (1) KR20230137342A (es)
CN (1) CN116802209A (es)
AU (1) AU2022217754A1 (es)
CA (1) CA3204225A1 (es)
CL (1) CL2023002285A1 (es)
CO (1) CO2023010002A2 (es)
CR (1) CR20230366A (es)
DO (1) DOP2023000149A (es)
EC (1) ECSP23058246A (es)
IL (1) IL304219A (es)
MX (1) MX2023009006A (es)
PE (1) PE20240233A1 (es)
WO (1) WO2022169757A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017373746A1 (en) * 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
US11384141B2 (en) * 2018-04-24 2022-07-12 National Research Council Of Canada Serum albumin binding antibodies for tuneable half-life extension of biologics
AU2020321977C1 (en) * 2019-07-31 2024-04-18 Eli Lilly And Company Relaxin analogs and methods of using the same

Also Published As

Publication number Publication date
CR20230366A (es) 2023-10-03
EP4288452A1 (en) 2023-12-13
CN116802209A (zh) 2023-09-22
IL304219A (en) 2023-09-01
WO2022169757A1 (en) 2022-08-11
AU2022217754A1 (en) 2023-07-27
KR20230137342A (ko) 2023-10-04
CA3204225A1 (en) 2022-08-11
DOP2023000149A (es) 2023-09-15
PE20240233A1 (es) 2024-02-16
JP2024506145A (ja) 2024-02-09
CL2023002285A1 (es) 2024-02-23
MX2023009006A (es) 2023-08-08
CO2023010002A2 (es) 2023-09-08

Similar Documents

Publication Publication Date Title
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2022002828A1 (es) Inhibidores de kras tricíclicos fusionados.
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
ECSP109934A (es) Compuesto - 946
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
ECSP23058246A (es) Fracciones que prolongan la semivida y métodos de uso de estas
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular